510(k) Report

510(k) · Cleared

Cleared

BD Phoenix Automated Microbiology System Tigecycline (0.25-16 UG/ML)

K132909510(k) TraditionalCleared Feb 14, 2014150-day reviewClass II21 CFR 866.1645

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Becton, Dickinson and Company · LON System, Test, Automated, Antimicrobial Susceptibility, Short Incubation

Cleared on Feb 14, 2014 after a 150-day review. The summary cites one number, which could not be confirmed as its predicate (see the table below). 4 later devices descend from it.

Decided
Feb 14, 2014
Review
150 days
Class
Class II
Product code
LON
Recalls
None
Predicates
1

4 later devices descend from it, 3 citing it directly.

Descendants, by year cleared 2018: 1 descendant cleared2019: 1 descendant cleared2025: 1 descendant cleared2023: 1 descendant cleared2010201520202025
  1. This deviceK132909 BD Phoenix Automated Microbiology System Tigecycline (0.25-16 UG/ML)Becton, Dickinson and Company · 2014
  2. Descendant · cites it directly · 1 of its ownK190905 BD Phoenix Automated Microbiology System – GN Ceftaroline (0.0156-4…Becton, Dickinson and Company · 2019
  3. Descendant · cites it directly · 0 of its ownK251713 BD Phoenix Automated Microbiology System - GN Eravacycline (0.125-2…Becton, Dickinson and Company · 2025
  4. Descendant · 2 generations on · 0 of its ownK211748 Selux AST System; Model AST Gen 1.0Selux Diagnostics, Inc. · 2023
  5. Descendant · cites it directly · 0 of its ownK173252 BD Phoenix Automated Microbiology System - GN Ceftolozane/tazobactam…Becton, Dickinson and Company · 2018

Most influential descendants

Showing 4 of 4 · See all
  • K190905BD Phoenix Automated Microbiology System – GN Ceftaroline (0.0156-4 µg/mL)Becton, Dickinson and Company · 2019 · cites it directly1descendant
  • K251713BD Phoenix Automated Microbiology System - GN Eravacycline (0.125-2 µg/mL)Becton, Dickinson and Company · 2025 · cites it directly0descendants
  • K211748Selux AST System; Model AST Gen 1.0Selux Diagnostics, Inc. · 2023 · 2 generations on0descendants
  • K173252BD Phoenix Automated Microbiology System - GN Ceftolozane/tazobactam (0.25/4-32/4 ug/mL)Becton, Dickinson and Company · 2018 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)K132909BD Phoenix Automated Microbiology System Tigecycline (0.25-16 UG/ML)Becton, Dickinson and Company2014—
+1K190905BD Phoenix Automated Microbiology System – GN Ceftaroline (0.0156-4 µg/mL)Becton, Dickinson and Company2019—
+1K251713BD Phoenix Automated Microbiology System - GN Eravacycline (0.125-2 µg/mL)Becton, Dickinson and Company2025—
+2K211748Selux AST System; Model AST Gen 1.0Selux Diagnostics, Inc.2023—
+1K173252BD Phoenix Automated Microbiology System - GN Ceftolozane/tazobactam…Becton, Dickinson and Company2018—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201810
201910
202310
202510
FIG. 1 — Lineage of K132909, 2014–2025Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LON? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new LON device

  1. #1 K260619 VITEK 2 AST-Streptococcus Cefepime (<=0.06 –…score 13.3 · 5 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary; numbers the summary cites that cannot be its predicate are marked – and kept off the family tree.

TypeNumberDeviceApplicantDecidedRecalls
Kept off the family treeP050510VITEK® System
Not in FDA’s 510(k), De Novo or PMA lists as we hold them (a misreading, a typo, or a number FDA does not list), so it is kept off the family tree

What descends from it? (4)

3 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K190905BD Phoenix Automated Microbiology System – GN Ceftaroline (0.0156-4 µg/mL)Becton, Dickinson and Company20191
K251713BD Phoenix Automated Microbiology System - GN Eravacycline (0.125-2 µg/mL)Becton, Dickinson and Company20250
K173252BD Phoenix Automated Microbiology System - GN Ceftolozane/tazobactam (0.25/4-32/4 ug/mL)Becton, Dickinson and Company20180

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K190905 (Becton, Dickinson and Company, 2019) has gone furthest, with 1 descendant of its own.

How does its category compare?

All LON devices

LON System, Test, Automated, Antimicrobial Susceptibility, Short Incubation: FDA decisions, review times, recalls and adverse event reports over 20 years. 2014, this device’s year, is highlighted.

FDA decisions per year · LON

5in 2025

2007: 192008: 72009: 82010: 12011: 82012: 102013: 72014: 42016: 32017: 102018: 42019: 82020: 52021: 52022: 82023: 112024: 22025: 52026 (partial year): 4
2007high 19 (2007) · low 0 (2015)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LON

90in 2025

2007: 50 days median2008: 66 days median2009: 76 days median2011: 85 days median2012: 200 days median2013: 115 days median2014: 90 days median2016: 242 days median2017: 89 days median2018: 88 days median2019: 84 days median2020: 81 days median2021: 268 days median2022: 189 days median2023: 210 days median2025: 90 days median2026 (partial year): 146 days median
2007high 268 (2021) · low 50 (2007)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · LON

1in 2025

2008: 12010: 1162011: 32012: 32014: 2, 2 Class I2016: 22017: 12018: 62019: 12020: 82022: 152024: 12025: 12026 (partial year): 6
2007high 116 (2010) · low 0 (2007)2026

Class I (2 since 2007) Class II/III not classified

Adverse event reports per year · LON

690in 2025

2007: 32008: 12010: 32011: 42012: 92013: 32014: 102015: 412016: 942017: 1972018: 5122019: 3152020: 2182021: 2322022: 1802023: 4532024: 4182025: 690
2007high 690 (2025) · low 0 (2009)2025

MAUDE reports naming product code LON, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
2007195003
200876611
200987600
20101—1163
201188534
20121020039
2013711503
20144902 (2)10
20150—041
20163242294
201710891197
20184886512
20198841315
20205818218
202152680232
2022818915180
2023112100453
20242—1418
20255901690
202641466—

What is it indicated for?

The BID PhoenixTM Automated Microbiology System is intended for in vitro quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) of most Gram-negative aerobic and facultative anaerobic bacteria isolates from pure culture for Enterobacteriaceae and Non-Enterobacteriaceae and most Gram-positive bacteria isolates from pure culture belonging to the genera Staphylococcus, Enterococcus and Streptococcus. This…

Read the full statement (133 words)

The BID PhoenixTM Automated Microbiology System is intended for in vitro quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) of most Gram-negative aerobic and facultative anaerobic bacteria isolates from pure culture for Enterobacteriaceae and Non-Enterobacteriaceae and most Gram-positive bacteria isolates from pure culture belonging to the genera Staphylococcus, Enterococcus and Streptococcus.

This premarket notification is for the addition of the antimicrobial agent Tigecycline at concentrations of 0.25 - l6pg/mL to Gram-negative ID/AST or AST only Phoenix panels. Tigecycline has been shown to be active in vitro against most strains of microorganisms listed below, as described in the FDA-approved package insert for this antimicrobial agent.

Active In Vitro and in Clinical Infections Against:

Citrobacter freundli Kiebsiella oxytoca

Enterobacter cloacae Kiebsiella pneumoniae

Esoherichia co/i

Active In Vitro

Serratia marcescens

Citrobacter koseri

Enterobacter aerogenes

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K132909: BD Phoenix Automated Microbiology System Tigecycline (0.25-16 UG/ML).” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K132909

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026